---
title: "RemeGen Deploys Idle Funds Into SPDB Wealth Products in Discloseable Transaction"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291552644.md"
description: "RemeGen (HK:9995) has triggered a discloseable transaction status under Hong Kong Listing Rules by deploying idle funds into Shanghai Pudong Development Bank wealth management products. The company allocated up to RMB2.5 billion in self-owned funds and RMB80 million in raised proceeds, with an additional RMB280 million recently added. This strategy aims to optimize cash management while maintaining principal protection. Analysts maintain a 'Buy' rating with a HK$129 price target."
datetime: "2026-07-02T12:38:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291552644.md)
  - [en](https://longbridge.com/en/news/291552644.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291552644.md)
---

# RemeGen Deploys Idle Funds Into SPDB Wealth Products in Discloseable Transaction

RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an update.

RemeGen Co., Ltd., a Hong Kong-listed Chinese biopharmaceutical company, is leveraging its idle self-owned funds and A-share proceeds to optimize cash management. The firm’s strategy includes allocating significant surplus capital into bank wealth management products while maintaining principal protection on portions funded by raised proceeds.

The board has approved the purchase of up to RMB2.5 billion in wealth management products with self-owned funds and up to RMB80 million with idle raised proceeds, and recently added RMB280 million in new products from SPDB’s Yantai branch. Aggregated across multiple agreements with the same bank over 12 months, these transactions have triggered discloseable transaction status under Hong Kong Listing Rules, requiring formal reporting and announcements to investors.

The most recent analyst rating on (HK:9995) stock is a Buy  
with a HK$129.00 price target.  
To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock,  
see the HK:9995 Stock Forecast page.

**More about RemeGen Co. Ltd. Class H**

RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China with limited liability and listed in Hong Kong under stock code 9995. The company operates in the biopharmaceutical sector, focusing on the research, development and commercialization of innovative biologic drugs, with a funding base that includes A-share proceeds from the mainland market.

RemeGen’s market presence spans both Hong Kong and domestic Chinese exchanges, giving it access to diversified capital sources. This dual-market positioning supports its capital-intensive R&D activities, and the company actively manages its liquidity by deploying idle self-owned funds and raised proceeds into short-term financial instruments to enhance overall returns.

**Average Trading Volume:** 4,332,750

**Technical Sentiment Signal:** Hold

**Current Market Cap:** HK$72.24B

For a thorough assessment of 9995 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [600000.CN](https://longbridge.com/en/quote/600000.CN.md)

## Related News & Research

- [RemeGen Clarifies Board Composition and Committee Roles](https://longbridge.com/en/news/289936377.md)
- [RemeGen Shareholders Back All Resolutions at 2025 AGM](https://longbridge.com/en/news/289949552.md)
- [Tele2 converts 2.66 million A shares into B shares](https://longbridge.com/en/news/294467376.md)
- [Weekly Recap: Plunge on low SkyNomad prices and HK$50M buyback](https://longbridge.com/en/news/294616380.md)
- [Zhihu files HKEX next-day disclosure return reporting 371,436 Class B-to-A share conversions](https://longbridge.com/en/news/294059412.md)